Literature DB >> 8308511

Uses and safety of acyclovir in pregnancy.

J G Spangler1, J K Kirk, M P Knudson.   

Abstract

Acyclovir, an antiviral nucleoside analogue, is a widely used agent highly specific for herpes simplex and varicella-zoster viruses. Unintended exposure to acyclovir early in pregnancy, which is not uncommon, may cause excessive maternal and physician anxiety. This drug has not been studied prospectively in large numbers of pregnant women and lacks the Food and Drug Administration's approval for gestational use unless benefits clearly outweigh potential fetal harm. However, data published since acyclovir became available do not indicate increased adverse effects related to its use in pregnancy, especially if prescribed in selected situations, such as disseminated primary herpes simplex infections or maternal varicella pneumonia. This article reports the impact of inadvertent acyclovir exposure on a woman during the first trimester of pregnancy and reviews the literature on acyclovir's pharmacology, safety profile, and potential uses during pregnancy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8308511

Source DB:  PubMed          Journal:  J Fam Pract        ISSN: 0094-3509            Impact factor:   0.493


  3 in total

1.  Pharmacokinetics of intravenous acyclovir, zidovudine, and acyclovir-zidovudine in pregnant rats.

Authors:  Stacy D Brown; Michael G Bartlett; Catherine A White
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

Review 2.  Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection.

Authors:  Jairam R Lingappa; Connie Celum
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Empirical treatment with parenteral acyclovir in a child with herpes simplex virus hepatitis and acute lymphoblastic leukemia.

Authors:  Nesreen A Faqih; Mahmoud A Alfaqih; Khadra Salami; Brian Herron; Iyad Sultan; Maysa Al-Hussaini
Journal:  IDCases       Date:  2018-02-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.